[Exercise-induced vasospastic angina].
Hikita
Hiroyuki
H
Cardiovascular Center, Yokosuka Kyosai Hospital.
Sato
Akira
A
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000787:Angina Pectoris / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004730:Endothelium, Vascular / Q000378:metabolism; D004837:Epinephrine / Q000378:metabolism / Q000502:physiology; D015444:Exercise / Q000502:physiology*; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D013564:Sympathetic Nervous System / Q000378:metabolism / Q000502:physiology; D054460:rho-Associated Kinases / Q000502:physiology
D002121:Calcium Channel Blockers; D047428:Protein Kinase Inhibitors; D009569:Nitric Oxide; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D054460:rho-Associated Kinases; C049347:fasudil; D009638:Norepinephrine; D004837:Epinephrine